Ensuring Access to Novel Alzheimer’s and Dementia Treatments: Evaluating Innovative Payment Approaches
确保获得新型阿尔茨海默病和痴呆症治疗方法:评估创新的支付方式
基本信息
- 批准号:9789172
- 负责人:
- 金额:$ 61.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-30 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcademyAddressAffectAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease related dementiaAmericanAmericasAmyloid beta-ProteinAreaBiological MarkersBrainCardiovascular DiseasesCaregiversCerebrospinal FluidClinicalClinical TrialsCognitiveCommunicable DiseasesConsensusCosts and BenefitsDementiaDiseaseDisease ProgressionDoseEarly treatmentEconomic ModelsEconomicsEducational workshopElderlyEnsureFamily CaregiverFormulariesFutureGenotypeGoalsHIV/HCVHealth PolicyHealth Services AccessibilityImpaired cognitionIncentivesIncidenceInsurance CarriersInterventionLifeLiteratureLongitudinal StudiesMalignant NeoplasmsManufacturer NameMapsMeasuresMediationMedicalMedical TechnologyMedicare/MedicaidMedicineMethodsModelingMonitorNeurobehavioral ManifestationsNeurosciencesOutcomePatientsPharmaceutical PreparationsPoliciesPolicy MakerPolicy ResearchPopulationPrevalencePricePrivatizationProcessQuality of lifeReimbursement MechanismsReportingResearchSavingsStructureSystemTechnologyTestingTimeVariantWorkalternative treatmentbasebehavioral healthcaregivingclinical Diagnosisclinical practicecostdementia caredesigndrug candidateeconomic outcomeeffective interventioneffective therapyfunctional statushealth economicsinformal caregiverinnovationmeetingsmortality riskneuroimagingnovelnovel therapeuticsoptimismpatient subsetspaymentphysical conditioningpopulation healthsocialsuccesstau Proteinstau aggregationtau-1theoriestrend
项目摘要
Project Summary/Abstract
Progress against Alzheimer's disease and related dementias (ADRD) has been frustratingly slow, but effective
treatments may be on the horizon. Given the scale of ADRD and its costs, even modest efficacy in delaying
progression could have substantial social benefits. However, the scale of the ADRD problem also presents a
financing challenge. How can we afford new therapies for large numbers of ADRD patients and those who are
pre-symptomatic? This problem is exacerbated by the likelihood that clinical benefits will vary with disease stage,
genotype, or other unknown factors. Payers are reluctant to pay high prices per dose for therapies, especially
when these benefits may accumulate much later in life. We will bring together experts in economics,
neuroscience, and ADRD care to identify and quantify alternative reimbursement strategies that ensure better
access. First, using a variant of the RAND/UCLA appropriateness methods, we will identify the most promising
ADRD interventions, quantify their likelihood of success and expected clinical benefit, and assess whether these
benefits are likely to vary across patient subgroups. Second, we will map clinical trial endpoints used in the
current ADRD pipeline to broader quality-of-life outcomes – e.g., functional status, disease incidence, and
mortality risk – that can be used to estimate societal consequences. Third, drawing on economic theory and the
exitant literature, we will develop novel reimbursement mechanisms for ADRD therapies and characterize how
they would be structured. Fourth, we will adapt the Future Elderly Model (FEM), a well-validated microsimulation
model, to study the long-term health and economic consequences of new ADRD technologies, and to study how
these consequences would vary with different pricing mechanisms. We will study both average outcomes and
changes in disparities across ADRD patients for alternative technology and pricing scenarios. Fifth, we will use
the microsimulation model to study impacts of technologies and pricing scenarios on the health and economic
outcomes of informal caregivers for ADRD patients. Finally, we will convene a workshop to disseminate our
findings to key marketplace and policy stakeholders, and to generate discussion about potential next steps.
Together, the proposed research will develop and evaluate innovative strategies to ensure that current and future
ADRD patients gain access to novel therapies.
项目总结/摘要
对抗阿尔茨海默病和相关痴呆症(ADRD)的进展缓慢得令人沮丧,但有效
治疗方法可能就在眼前。考虑到ADRD的规模及其成本,即使是在延迟治疗方面的适度疗效,
进步可以带来巨大的社会效益。然而,ADRD问题的规模也提出了一个
融资挑战。我们如何为大量的ADRD患者和那些
症状前这个问题由于临床益处将随疾病阶段而变化的可能性而加剧,
基因型或其他未知因素。支付者不愿意为每剂治疗支付高价,
这些好处可能会在以后的生活中积累起来。我们将召集经济学专家,
神经科学和ADRD护理,以确定和量化替代报销策略,确保更好地
access.首先,使用兰德/加州大学洛杉矶分校的适当性方法的变体,我们将确定最有前途的
ADRD干预措施,量化其成功的可能性和预期的临床获益,并评估这些措施是否
受益可能因患者亚组而异。其次,我们将绘制临床试验终点图,
目前ADRD管道更广泛的生活质量结果-例如,功能状态、疾病发生率,以及
死亡风险-可用于估计社会后果。第三,借鉴经济理论,
现有文献,我们将开发新的ADRD治疗报销机制,并描述如何
他们将被组织起来。第四,我们将调整未来老年人模型(FEM),这是一个经过充分验证的微观模拟
模型,研究新的ADRD技术的长期健康和经济后果,并研究如何
这些后果会因定价机制不同而有所不同。我们将研究平均结果,
ADRD患者在替代技术和定价方案方面的差异变化。第五,我们将使用
微观模拟模型,研究技术和定价方案对健康和经济的影响
ADRD患者的非正式照顾者的结局。最后,我们将举办一个研讨会,
调查结果提供给主要市场和政策利益相关者,并就潜在的后续步骤展开讨论。
总之,拟议的研究将制定和评估创新战略,以确保当前和未来
ADRD患者可以获得新的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANA P GOLDMAN其他文献
DANA P GOLDMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANA P GOLDMAN', 18)}}的其他基金
Center for Advancing Sociodemographic and Economic Study of Alzheimer’s Disease and Related Dementias (CeASES-ADRD)
阿尔茨海默病及相关痴呆症社会人口学和经济研究推进中心 (CeASES-ADRD)
- 批准号:
10216946 - 财政年份:2020
- 资助金额:
$ 61.65万 - 项目类别:
Center for Advancing Sociodemographic and Economic Study of Alzheimer’s Disease and Related Dementias (CeASES-ADRD)
阿尔茨海默病及相关痴呆症社会人口学和经济研究推进中心 (CeASES-ADRD)
- 批准号:
10417203 - 财政年份:2020
- 资助金额:
$ 61.65万 - 项目类别:
Center for Advancing Sociodemographic and Economic Study of Alzheimer’s Disease and Related Dementias (CeASES-ADRD)
阿尔茨海默病及相关痴呆症社会人口学和经济研究推进中心 (CeASES-ADRD)
- 批准号:
10657377 - 财政年份:2020
- 资助金额:
$ 61.65万 - 项目类别:
Ensuring Access to Novel Alzheimer’s and Dementia Treatments: Evaluating Innovative Payment Approaches
确保获得新型阿尔茨海默病和痴呆症治疗方法:评估创新的支付方式
- 批准号:
9977782 - 财政年份:2018
- 资助金额:
$ 61.65万 - 项目类别:
Ensuring Access to Novel Alzheimer’s and Dementia Treatments: Evaluating Innovative Payment Approaches
确保获得新型阿尔茨海默病和痴呆症治疗方法:评估创新的支付方式
- 批准号:
10176332 - 财政年份:2018
- 资助金额:
$ 61.65万 - 项目类别:
The Long-Term Benefits of Interventions to Improve T2D Outcomes
改善 T2D 结局的干预措施的长期益处
- 批准号:
9176837 - 财政年份:2016
- 资助金额:
$ 61.65万 - 项目类别:
The Long-Term Benefits of Interventions to Improve T2D Outcomes
改善 T2D 结局的干预措施的长期益处
- 批准号:
9321379 - 财政年份:2016
- 资助金额:
$ 61.65万 - 项目类别:
USC Resource Center for Minority Aging Research (US-RCMAR)
南加州大学少数民族老龄化研究资源中心 (US-RCMAR)
- 批准号:
8987153 - 财政年份:2015
- 资助金额:
$ 61.65万 - 项目类别:
Technological Innovation in Health Care and the Long-Term Fiscal Outlook
医疗保健技术创新和长期财政前景
- 批准号:
8750769 - 财政年份:2014
- 资助金额:
$ 61.65万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 61.65万 - 项目类别:
Research Grant